Alfonso Galderisi, MD, PhD
he/him/his
Assistant ProfessorCards
About
Research
Publications
2025
ATGL links insulin dysregulation to insulin resistance in adolescents with obesity and hepatosteatosis
Slusher A, Santoro N, Vash-Margita A, Galderisi A, Hu P, Tokoglu F, Li Z, Tarabra E, Strober J, Vatner D, Shulman G, Caprio S. ATGL links insulin dysregulation to insulin resistance in adolescents with obesity and hepatosteatosis. Journal Of Clinical Investigation 2025, 135: e184740. PMID: 40091831, PMCID: PMC11910223, DOI: 10.1172/jci184740.Peer-Reviewed Original ResearchConceptsHyperinsulinemic-euglycemic clampSubcutaneous adipose tissueInsulin resistanceAdipose triglyceride lipaseInsulin infusionOral glucose tolerance testAbdominal fat distributionGlucose tolerance testMeasuring abdominal fat distributionLower liver fatActivating adipose triglyceride lipaseMetabolic disease riskLiver fat contentEctopic lipid storageFUNDINGThis workAdipose tissue lipolysisInhibition of adipose tissue lipolysisSubcutaneous adipose tissue samplesFat distributionTolerance testInsulin exposureLiver fatInfusionGlycerol turnoverAdipose tissueMetabolic Phenotype of Stage 1 and Stage 2 Type 1 Diabetes Using Modeling of β Cell Function
Galderisi A, Bonet J, Ismail H, Moran A, Fiorina P, Bosi E, Petrelli A. Metabolic Phenotype of Stage 1 and Stage 2 Type 1 Diabetes Using Modeling of β Cell Function. The Journal Of Clinical Endocrinology & Metabolism 2025, dgaf086. PMID: 39992257, DOI: 10.1210/clinem/dgaf086.Peer-Reviewed Original ResearchOral glucose tolerance testMetabolic phenotypeOral minimal modelInsulin secretionResponse to disease-modifying treatmentsOdds of disease progressionPhenotype of individualsPrevention trialsPreclinical type 1 diabetesIndependent of stageMeasures of beta-cell functionStage 1Glucose tolerance testAssociated with reduced oddsBeta-cell functionMeasures of insulin secretionType 1 diabetesOGTT-derived measuresIncreased insulin clearanceT1D prevention trialsIslet autoimmunityDisease-modifying treatmentsTolerance testDisease progressionProgression predictorsEffect of Elexacaftor/Tezacaftor/Ivacaftor on Glucose Tolerance in Adolescents With Cystic Fibrosis
Galderisi A, Weiss L, Besançon A, Stremler N, Reix P, Wizla N, Lustre A, Rames C, Tatopoulos A, Perisson C, Dalphin M, Troussier F, Houdouin V, Bessaci K, Cosson L, Gabsi A, Corvol H, Deneuville E, Storni V, Ramel S, Bui S, Heraud M, Remus N, Huet F, Scalbert M, Mely L, Gachelin E, Giannantonio M, Letierce A, Sahki D, Marguet C, Bonnel A, Sermet-Gaudelus I. Effect of Elexacaftor/Tezacaftor/Ivacaftor on Glucose Tolerance in Adolescents With Cystic Fibrosis. The Journal Of Clinical Endocrinology & Metabolism 2025, dgaf099. PMID: 39977216, DOI: 10.1210/clinem/dgaf099.Peer-Reviewed Original ResearchOral glucose tolerance testBaseline oral glucose tolerance testAbnormal glucose toleranceNormal glucose toleranceAbnormal glucose tolerance groupCystic fibrosisGlucose toleranceNormal glucose tolerance groupEffective CFTR modulatorsCF-related diabetesInsulin secretionImpaired fasting glucoseGlucose tolerance testImpaired glucose toleranceForced expiratory volumeBMIz-scoreCFTR modulatorsBaseline characteristicsRelated diabetesFasting glucoseTolerance testTherapeutic strategiesInsulin treatmentExpiratory volumeGlucose levels
2024
Daily glucose variability is associated with intrahepatic fat content, β cell sensitivity, and biomarkers of glycolysis in youth with obesity
Barbieri E, Bonet J, Fox D, Nelson R, Nelson M, Nelson L, Fernandez C, Van Name M, Samuels S, Caprio S, Sabati M, Galderisi A, Sherr J, Man C, Santoro N. Daily glucose variability is associated with intrahepatic fat content, β cell sensitivity, and biomarkers of glycolysis in youth with obesity. Obesity 2024, 33: 116-124. PMID: 39658509, PMCID: PMC11666407, DOI: 10.1002/oby.24175.Peer-Reviewed Original ResearchConceptsIntrahepatic fat contentDaily glucose variabilityLiver proton density fat fractionProton density fat fractionGlucose variabilityInsulin sensitivityOral glucose tolerance testFat fractionInsulin secretionAssociated with insulin resistanceFirst-phase insulin secretionAssociated with 2-h glucoseGlucose tolerance testGlucose standard deviationMagnetic resonance imagingOral minimal modelCoefficient of variationBasal insulin secretionPediatric obesityPostprandial glucoseTolerance testCell sensitivityInsulin resistanceObesityResonance imagingCorrection: Quantifying beta cell function in the preclinical stages of type 1 diabetes
Galderisi A, Carr A, Martino M, Taylor P, Senior P, Dayan C. Correction: Quantifying beta cell function in the preclinical stages of type 1 diabetes. Diabetologia 2024, 68: 472-473. PMID: 39592509, PMCID: PMC11732860, DOI: 10.1007/s00125-024-06335-w.Peer-Reviewed Original ResearchContinuous Glucose Monitoring among Infants Born Very Preterm: Evidence for Accuracy in Neonatal Intensive Care
Bonet J, Guiducci S, Res G, Brigadoi S, Sen S, Montaldo P, Priante E, Santoro N, Trevisanuto D, Baraldi E, Dalla Man C, Galderisi A. Continuous Glucose Monitoring among Infants Born Very Preterm: Evidence for Accuracy in Neonatal Intensive Care. The Journal Of Pediatrics 2024, 278: 114416. PMID: 39579867, DOI: 10.1016/j.jpeds.2024.114416.Peer-Reviewed Original ResearchBlood glucoseContinuous glucose monitoringSensor glucoseNeonatal intensive care unitInfants born pretermWeeks of gestationNeonatal intensive careIntensive care unitVery pretermGlucose monitoringCare unitIntensive carePoint-of-care blood glucoseInfantsPretermNeonatesPaired measurementsCGM accuracyHoursBirthweightGestationGlucoseBirthWeeksTrajectory of beta cell function and insulin clearance in stage 2 type 1 diabetes: natural history and response to teplizumab
Galderisi A, Sims E, Evans-Molina C, Petrelli A, Cuthbertson D, Nathan B, Ismail H, Herold K, Moran A. Trajectory of beta cell function and insulin clearance in stage 2 type 1 diabetes: natural history and response to teplizumab. Diabetologia 2024, 68: 646-661. PMID: 39560746, PMCID: PMC11832608, DOI: 10.1007/s00125-024-06323-0.Peer-Reviewed Original ResearchProgrammed death-1AUC C-peptideSlow progressorsRapid progressorsInsulin secretionInsulin clearanceC-peptideDisease-free survival ratesT effector memory cellsCD8+ T effector memory cellsNatural historyImpact of immunotherapyPlacebo-treated individualsT memory cellsBaseline insulin secretionBeta cell functionInterpreting clinical trialsLoss of insulin secretionDeath-1Elevated insulin secretionPlacebo-treatedTreatment armsTeplizumabClinical trialsDisposition indexAdipose tissue insulin resistance in children and adolescents: linking glucose and free fatty acid metabolism to hepatic injury markers
Bonet J, Weiss R, Galderisi A, Man C, Caprio S, Santoro N. Adipose tissue insulin resistance in children and adolescents: linking glucose and free fatty acid metabolism to hepatic injury markers. AJP Endocrinology And Metabolism 2024, 327: e723-e728. PMID: 39503461, PMCID: PMC11684862, DOI: 10.1152/ajpendo.00270.2024.Peer-Reviewed Original ResearchImpaired glucose toleranceInsulin sensitivity indexAlanine transaminaseInsulin resistanceFree fatty acid metabolismInsulin sensitivityP<10<sup>-6</sup>Years of follow-upMeasurement of liver function testsLiver function testsFree fatty acidsAdipose tissue insulin resistanceAdipose tissue insulin sensitivityHepatic injury markersPlasma alanine transaminaseEstimated insulin sensitivity indexTissue insulin sensitivityMann-Whitney testTissue insulin resistanceType 2 diabetesDevelopment of insulin resistanceProgression of insulin resistanceOral minimal modelCardiometabolic complicationsInsulin-resistant states689 Triple CFTR modulator combination improves glucose tolerance in adolescents with cystic fibrosis: data from the French observational pediatric study MODUL-CF
Weiss L, Galderisi A, Besançon A, Stremler N, Reix P, Wizla N, Rames C, Marguet C, Tatapoulos A, Perrisson C, Dalphin M, Troussier F, Houdouin V, Abely M, Cosson L, Gabsi A, Corvol H, Deneuville E, Sahki D, Bonnel A, Group M, Sermet-Gaudelus I. 689 Triple CFTR modulator combination improves glucose tolerance in adolescents with cystic fibrosis: data from the French observational pediatric study MODUL-CF. Journal Of Cystic Fibrosis 2024, 23: s386-s387. DOI: 10.1016/s1569-1993(24)01527-3.Peer-Reviewed Original ResearchRevisiting the Pattern of Loss of β-Cell Function in Preclinical Type 1 Diabetes.
Martino M, Galderisi A, Evans-Molina C, Dayan C. Revisiting the Pattern of Loss of β-Cell Function in Preclinical Type 1 Diabetes. Diabetes 2024, 73: 1769-1779. PMID: 39106185, DOI: 10.2337/db24-0163.Peer-Reviewed Original ResearchB cell functionBeta cell lossType 1 diabetesLoss of B-cell functionCell lossOral glucose tolerance testPreclinical type 1 diabetesEarly stage diseaseBeta cell destructionTime of diagnosisDestruction of B cellsGlucose tolerance testMonths prior to clinical diagnosisAntibody positivityStage diseaseDisease activityAutoimmune destructionB cellsDisease accelerationInsulin therapyTolerance testInsulin secretionSubmaximal stimuliCell destructionGlucose control
Academic Achievements & Community Involvement
News & Links
Get In Touch
Contacts
Mailing Address
Pediatric Endocrinology & Diabetes
333 Cedar Street
New Haven, Connecticut 35120
United States